OrthoPediatrics (NASDAQ:KIDS) Price Target Raised to $20.00

OrthoPediatrics (NASDAQ:KIDS) had its price target raised by Truist Financial from $17.00 to $20.00 in a research report report published on Thursday, Marketbeat.com reports. Truist Financial currently has a hold rating on the stock.

Several other brokerages also recently weighed in on KIDS. Canaccord Genuity Group set a $25.00 price target on shares of OrthoPediatrics in a report on Friday, April 24th. TD Cowen reissued a “buy” rating on shares of OrthoPediatrics in a research note on Monday, June 15th. BTIG Research restated a “buy” rating and set a $24.00 price objective on shares of OrthoPediatrics in a research report on Friday, May 1st. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of OrthoPediatrics in a research note on Tuesday, April 21st. Nine research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, OrthoPediatrics currently has a consensus rating of “Moderate Buy” and a consensus price target of $24.78.

OrthoPediatrics Stock Performance

Shares of KIDS opened at $19.22 on Thursday. The company has a quick ratio of 2.37, a current ratio of 5.21 and a debt-to-equity ratio of 0.29. The business has a 50-day simple moving average of $18.66 and a two-hundred day simple moving average of $17.70. The stock has a market cap of $493.57 million, a price-to-earnings ratio of -11.44 and a beta of 0.99. OrthoPediatrics has a 52 week low of $14.42 and a 52 week high of $23.70.

OrthoPediatrics (NASDAQ:KIDS) last posted its quarterly earnings data on Thursday, April 30th. The company reported ($0.42) EPS for the quarter, topping the consensus estimate of ($0.46) by $0.04. The firm had revenue of $59.36 million for the quarter, compared to the consensus estimate of $58.28 million. OrthoPediatrics had a negative return on equity of 7.01% and a negative net margin of 16.31%. On average, analysts expect that OrthoPediatrics will post -1.13 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Russell Investments Group Ltd. raised its stake in shares of OrthoPediatrics by 433.1% during the third quarter. Russell Investments Group Ltd. now owns 1,402 shares of the company’s stock valued at $26,000 after acquiring an additional 1,139 shares in the last quarter. Northwestern Mutual Wealth Management Co. grew its stake in OrthoPediatrics by 5,226.5% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 2,610 shares of the company’s stock worth $46,000 after purchasing an additional 2,561 shares in the last quarter. Caption Management LLC bought a new position in OrthoPediatrics in the third quarter worth approximately $54,000. BNP Paribas Financial Markets increased its holdings in OrthoPediatrics by 60.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 3,288 shares of the company’s stock worth $61,000 after purchasing an additional 1,235 shares during the period. Finally, State of Wyoming increased its holdings in OrthoPediatrics by 189.7% during the 4th quarter. State of Wyoming now owns 6,822 shares of the company’s stock worth $121,000 after purchasing an additional 4,467 shares during the period. Institutional investors own 69.05% of the company’s stock.

OrthoPediatrics Company Profile

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.